2 Companies Testing Dengue Vaccines 2023

According to the Director General of the Indian Council of Medical Research, Dr. Rajeev Bahl, two different businesses are now undertaking tests to produce a dengue vaccine.

According to the current state of the vaccination studies, Panacea has completed phase l/ll, and the trials have been carried out on a total of one hundred people ranging in age from 18 to 60 years old.

The examination of safety, immunogenicity, and viremia will be the key focuses of this research. Now, the business intends to begin phase 3 randomized studies, which will be double-blind, placebo-controlled trials on 10,335 healthy persons aged 18 to 80 years across 20 locations of the ICMR. The approval for these studies was given in January of 2023.

There are currently 2 Dengue Vaccine Development Companies Engaged in Trials.

Dr. Bahl stated the following while he was speaking to ANI: “The company that was supposed to make the products three months ago was unable to do so.” Having said that, the business may now be ready in the month of August. Therefore, we will begin such experiments when we go into phase three.”

He continued by saying, “As of right now, we are unable to say anything, not even about efficacy.”

According to the presentation that was given by ICMR at the press event, another business called Serum Institute of India (SII) has finished phase one studies on 60 individuals with the goal of evaluating their level of safety.